Published in J Cyst Fibros on February 10, 2013
Time between collection and storage significantly influences bacterial sequence composition in sputum samples from cystic fibrosis respiratory infections. J Clin Microbiol (2014) 1.02
Polybacterial human disease: the ills of social networking. Trends Microbiol (2014) 1.01
Analysis of Lung Microbiota in Bronchoalveolar Lavage, Protected Brush and Sputum Samples from Subjects with Mild-To-Moderate Cystic Fibrosis Lung Disease. PLoS One (2016) 0.84
Universal digital high-resolution melt: a novel approach to broad-based profiling of heterogeneous biological samples. Nucleic Acids Res (2013) 0.84
Respiratory microbiota resistance and resilience to pulmonary exacerbation and subsequent antimicrobial intervention. ISME J (2015) 0.83
Implications of multiple freeze-thawing on respiratory samples for culture-independent analyses. J Cyst Fibros (2014) 0.82
A French multicentric study and review of pulmonary Nocardia spp. in cystic fibrosis patients. Med Microbiol Immunol (2014) 0.82
Pulmonary nocardiosis in an immunocompetent patient with cystic fibrosis. Case Rep Pulmonol (2015) 0.75
A CFTR potentiator in patients with cystic fibrosis and the G551D mutation. N Engl J Med (2011) 8.73
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 5.51
Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med (2008) 3.91
Lung clearance index is a repeatable and sensitive indicator of radiological changes in bronchiectasis. Am J Respir Crit Care Med (2014) 3.50
Partitioning core and satellite taxa from within cystic fibrosis lung bacterial communities. ISME J (2010) 2.55
Simvastatin decreases lipopolysaccharide-induced pulmonary inflammation in healthy volunteers. Am J Respir Crit Care Med (2009) 2.52
Extravascular lung water indexed to predicted body weight is a novel predictor of intensive care unit mortality in patients with acute lung injury. Crit Care Med (2010) 2.49
Lung microbiota and bacterial abundance in patients with bronchiectasis when clinically stable and during exacerbation. Am J Respir Crit Care Med (2013) 2.08
The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One (2012) 2.03
Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros (2012) 1.79
Propionibacterium acnes types I and II represent phylogenetically distinct groups. J Clin Microbiol (2005) 1.75
A randomized clinical trial of hydroxymethylglutaryl- coenzyme a reductase inhibition for acute lung injury (The HARP Study). Am J Respir Crit Care Med (2010) 1.67
Does bacterial density in cystic fibrosis sputum increase prior to pulmonary exacerbation? J Cyst Fibros (2011) 1.53
Formation of Propionibacterium acnes biofilms on orthopaedic biomaterials and their susceptibility to antimicrobials. Biomaterials (2003) 1.50
MRSA in companion animals. Vet Rec (2006) 1.40
Respiratory viral infection in exacerbations of COPD. Respir Med (2008) 1.35
Staphylococcus aureus small-colony variants are independently associated with worse lung disease in children with cystic fibrosis. Clin Infect Dis (2013) 1.34
Analysis of the bacterial communities present in lungs of patients with cystic fibrosis from American and British centers. J Clin Microbiol (2010) 1.32
CAMP factor homologues in Propionibacterium acnes: a new protein family differentially expressed by types I and II. Microbiology (2005) 1.28
Antifungal photodynamic therapy. Microbiol Res (2007) 1.20
Population structure and characterization of viridans group streptococci (VGS) including Streptococcus pneumoniae isolated from adult patients with cystic fibrosis (CF). J Cyst Fibros (2010) 1.17
Diagnostic accuracy of heart-type fatty acid-binding protein for the early diagnosis of acute myocardial infarction. Am J Emerg Med (2011) 1.15
Microneedle arrays allow lower microbial penetration than hypodermic needles in vitro. Pharm Res (2009) 1.14
Dysregulated apoptosis and NFkappaB expression in COPD subjects. Respir Res (2009) 1.12
Incidence and risk factors for pulmonary exacerbation treatment failures in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa. Chest (2011) 1.09
Decreased levels of secretory leucoprotease inhibitor in the Pseudomonas-infected cystic fibrosis lung are due to neutrophil elastase degradation. J Immunol (2009) 1.07
Potential of photodynamic therapy in treatment of fungal infections of the mouth. Design and characterisation of a mucoadhesive patch containing toluidine blue O. J Photochem Photobiol B (2006) 1.07
Early detection of Pseudomonas aeruginosa--comparison of conventional versus molecular (PCR) detection directly from adult patients with cystic fibrosis (CF). Ann Clin Microbiol Antimicrob (2004) 1.04
Clinical trials in cystic fibrosis. J Cyst Fibros (2007) 1.03
Multicenter randomized controlled trial of withdrawal of inhaled corticosteroids in cystic fibrosis. Am J Respir Crit Care Med (2006) 1.02
Towards "molecular Esperanto" or the Tower of Babel? (the need for harmonization of techniques for genotyping clinical isolates of Pseudomonas aeruginosa isolated from patients with cystic fibrosis). J Clin Microbiol (2003) 1.01
Prevalence of methicillin-resistant Staphylococcus aureus colonization in residents and staff in nursing homes in Northern Ireland. J Am Geriatr Soc (2009) 1.00
Antibiotic management of lung infections in cystic fibrosis. I. The microbiome, methicillin-resistant Staphylococcus aureus, gram-negative bacteria, and multiple infections. Ann Am Thorac Soc (2014) 1.00
Staphylococcus aureus enterotoxins induce IL-8 secretion by human nasal epithelial cells. Respir Res (2006) 1.00
Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis. Pediatr Pulmonol (2006) 0.99
Comparison of techniques to examine the diversity of fungi in adult patients with cystic fibrosis. Med Mycol (2010) 0.99
Evidence for physical therapies (airway clearance and physical training) in cystic fibrosis: an overview of five Cochrane systematic reviews. Respir Med (2006) 0.98
The effect of treatment of cystic fibrosis pulmonary exacerbations on airways and systemic inflammation. Pediatr Pulmonol (2007) 0.97
Evaluation of the ability of LL-37 to neutralise LPS in vitro and ex vivo. PLoS One (2011) 0.95
Drug delivery strategies for photodynamic antimicrobial chemotherapy: from benchtop to clinical practice. J Photochem Photobiol B (2009) 0.95
The relationship of clinical and inflammatory markers to outcome in stable patients with cystic fibrosis. Pediatr Pulmonol (2007) 0.95
Biomarkers of fruit and vegetable intake in human intervention studies: a systematic review. Crit Rev Food Sci Nutr (2011) 0.94
Role of CFTR, Pseudomonas aeruginosa and Toll-like receptors in cystic fibrosis lung inflammation. Biochem Soc Trans (2009) 0.94
Epidemiology of Burkholderia cepacia complex species recovered from cystic fibrosis patients: issues related to patient segregation. J Med Microbiol (2004) 0.93
Molecular characterization and phylogenetic analysis of quinolone resistance-determining regions (QRDRs) of gyrA, gyrB, parC and parE gene loci in viridans group streptococci isolated from adult patients with cystic fibrosis. J Antimicrob Chemother (2010) 0.93
Validity and reliability of cardiorespiratory measurements recorded by the LifeShirt during exercise tests. Respir Physiol Neurobiol (2009) 0.92
Development of a diagnostic PCR assay that targets a heat-shock protein gene (groES) for detection of Pseudomonas spp. in cystic fibrosis patients. J Med Microbiol (2003) 0.92
Acute and latent adenovirus in COPD. Respir Med (2007) 0.91
Bronchial epithelial cell growth regulation in fibroblast cocultures: the role of hepatocyte growth factor. Am J Physiol Lung Cell Mol Physiol (2007) 0.90
Do smokers with chronic obstructive pulmonary disease report their smoking status reliably? A comparison of self-report and bio-chemical validation. Int J Nurs Stud (2011) 0.90
Pandoraea apista isolated from a patient with cystic fibrosis: problems associated with laboratory identification. Br J Biomed Sci (2002) 0.90
Airway epithelial cell apoptosis and inflammation in COPD, smokers and nonsmokers. Eur Respir J (2012) 0.89
Comparison of nasal and bronchial epithelial cells obtained from patients with COPD. PLoS One (2012) 0.88
Ancestral haplotype 8.1 and lung disease severity in European cystic fibrosis patients. J Cyst Fibros (2011) 0.88
Antibiotic resistance in Prevotella species isolated from patients with cystic fibrosis. J Antimicrob Chemother (2013) 0.88
Lumacaftor-Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del CFTR. N Engl J Med (2015) 0.87
Molecular characterization of macrolide resistance determinants [erm(B) and mef(A)] in Streptococcus pneumoniae and viridans group streptococci (VGS) isolated from adult patients with cystic fibrosis (CF). J Antimicrob Chemother (2009) 0.87
Effect of cystic fibrosis exacerbations on neutrophil function. Int Immunopharmacol (2005) 0.87
Effect of Aspergillus fumigatus and Candida albicans on pro-inflammatory response in cystic fibrosis epithelium. J Cyst Fibros (2011) 0.87
Resistance development of cystic fibrosis respiratory pathogens when exposed to fosfomycin and tobramycin alone and in combination under aerobic and anaerobic conditions. PLoS One (2013) 0.87
Matrix metalloproteinases vary with airway microbiota composition and lung function in non-cystic fibrosis bronchiectasis. Ann Am Thorac Soc (2015) 0.86
A20 regulation of nuclear factor-κB: perspectives for inflammatory lung disease. Am J Respir Cell Mol Biol (2011) 0.86
Bacterial community diversity in cultures derived from healthy and inflamed ileal pouches after restorative proctocolectomy. Inflamm Bowel Dis (2009) 0.86
Characterization of bacterial community diversity in chronic rhinosinusitis infections using novel culture-independent techniques. Am J Rhinol Allergy (2011) 0.86
Epstein - Barr virus Pneumonitis. Ulster Med J (2009) 0.86
Development of a novel PCR assay for the identification of the black yeast, Exophiala (Wangiella) dermatitidis from adult patients with cystic fibrosis (CF). J Cyst Fibros (2008) 0.86
Development of novel oral formulations prepared via hot melt extrusion for targeted delivery of photosensitizer to the colon. Photochem Photobiol (2011) 0.86
Ex vivo diagnosis of lung cancer using a Raman miniprobe. J Phys Chem B (2009) 0.86
Airway clearance in bronchiectasis: a randomized crossover trial of active cycle of breathing techniques versus Acapella. Respiration (2005) 0.86
Comparison of sputum induction using high-output and low-output ultrasonic nebulizers in normal subjects and patients with COPD. Chest (2002) 0.86
Delivery of Methylene Blue and meso-tetra (N-methyl-4-pyridyl) porphine tetra tosylate from cross-linked poly(vinyl alcohol) hydrogels: a potential means of photodynamic therapy of infected wounds. J Photochem Photobiol B (2009) 0.85
Three clinically distinct chronic pediatric airway infections share a common core microbiota. Ann Am Thorac Soc (2014) 0.85
Emergence of Scedosporium apiospermum in patients with cystic fibrosis. Arch Dis Child (2007) 0.85
Photodynamic Antimicrobial Chemotherapy (PACT) in combination with antibiotics for treatment of Burkholderia cepacia complex infection. J Photochem Photobiol B (2011) 0.85
Effect of sub-lethal challenge with Photodynamic Antimicrobial Chemotherapy (PACT) on the antibiotic susceptibility of clinical bacterial isolates. J Photochem Photobiol B (2010) 0.85
Antimicrobial activity of fosfomycin and tobramycin in combination against cystic fibrosis pathogens under aerobic and anaerobic conditions. J Cyst Fibros (2011) 0.85
Quality of life and healthcare utilisation in cystic fibrosis: a multicentre study. Eur Respir J (2012) 0.85
Fosfomycin and tobramycin in combination downregulate nitrate reductase genes narG and narH, resulting in increased activity against Pseudomonas aeruginosa under anaerobic conditions. Antimicrob Agents Chemother (2013) 0.84
Expression of the inflammatory regulator A20 correlates with lung function in patients with cystic fibrosis. J Cyst Fibros (2012) 0.84
Toll-like receptor 4 is not targeted to the lysosome in cystic fibrosis airway epithelial cells. Am J Physiol Lung Cell Mol Physiol (2013) 0.84
The future of antimicrobial therapy in the era of antibiotic resistance in cystic fibrosis pulmonary infection. Expert Rev Respir Med (2013) 0.84
Improved molecular detection of Burkholderia cepacia genomovar III and Burkholderia multivorans directly from sputum of patients with cystic fibrosis. J Microbiol Methods (2002) 0.84
Antibiotic management of lung infections in cystic fibrosis. II. Nontuberculous mycobacteria, anaerobic bacteria, and fungi. Ann Am Thorac Soc (2014) 0.84
Antibiotic and anti-inflammatory therapies for cystic fibrosis. Cold Spring Harb Perspect Med (2013) 0.84
Modulation of gel formation and drug-release characteristics of lidocaine-loaded poly(vinyl alcohol)-tetraborate hydrogel systems using scavenger polyol sugars. Eur J Pharm Biopharm (2008) 0.83
Expert patient self-management program versus usual care in bronchiectasis: a randomized controlled trial. Arch Phys Med Rehabil (2011) 0.83
Macrolides and bronchiectasis: clinical benefit with a resistance price. JAMA (2013) 0.83
The use of culture-independent tools to characterize bacteria in endo-tracheal aspirates from pre-term infants at risk of bronchopulmonary dysplasia. J Perinat Med (2010) 0.82
Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis. Expert Rev Respir Med (2010) 0.82
Treatment adherence and health outcomes in patients with bronchiectasis. BMC Pulm Med (2014) 0.82